media – Page 6 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Regeneron’s “world’s first” gene therapy for deafness approved for market launch.

Hearing loss is one of the most common sensory impairments, affecting a large number of people. According to the World Hearing Report, more than 1.5 billion people currently suffer from varying degrees of hearing loss, and this number is expected to reach nearly 2.5 billion by 2050 . On April 23 , 2026 , Regeneron officially announced that the U.S. FDA had given accelerated approval to its investigational gene therapy Otarmeni ( lunsotogene parvec-cwha ), making it the first and currently only gene therapy approved for the treatment of hereditary hearing loss, and also Regeneron’s first approved gene therapy . The FDA emphasizes that this is the first therapy to directly address the molecular root causes of hereditary hearing loss. Scientifically, this represents a significant step forward in human medicine, moving from ” symptom treatment ” to ” gene repair . ” The success of Otarmeni not only validates the ...
- Source: drugdu
- 74
- April 27, 2026
Lunan Pharmaceutical Group’s miglitol raw material received approval from India’s DCGI

Recently, Lunan Pharmaceutical Group Lunan New Era Biotechnology Co., Ltd. received a drug registration certificate for miglitol issued by the DCGI (Drug Controller General of India, the highest administrative agency in India responsible for drug regulation). This is the second approval for the new process of miglitol raw material after it was approved by the MFDS in South Korea earlier this year. India holds a significant position in the global generic drug industry, and Lunan Pharmaceutical Group has established long-term, close, and friendly cooperative relationships with many well-known Indian pharmaceutical companies. The successful completion of this registration demonstrates our company’s strong capabilities in R&D, quality control, and registration management. Miglitol is an oral hypoglycemic agent belonging to the class of alpha-glucosidase inhibitors, primarily used to treat type 2 diabetes . It works by inhibiting alpha-glucosidase on the small intestinal mucosa, thus slowing the breakdown and absorption of carbohydrates and reducing ...
- Source: drugdu
- 52
- April 27, 2026
Dongbao Pharmaceutical’s human insulin raw materials have been approved for entry into the Pakistani market

According to Tonghua Dongbao, the company’s human insulin raw material product recently received approval from the National Drug Regulatory Authority of Pakistan, marking a new step forward in its internationalization strategy as the product can now be officially supplied to the Pakistani market. This approval was achieved by the company, as a supplier of human insulin raw materials, by supporting overseas clients in completing the registration and market approval of their formulation products in Pakistan, demonstrating the overseas competitiveness of the company’s raw material products. With over two decades of experience in the insulin field, the company has built a mature and stable large-scale raw material production system and a full life-cycle quality control system, enabling it to provide reliable and continuous raw material supplies to its global partners. Pakistan bears one of the heaviest burdens of diabetes globally. Data from the International Diabetes Federation shows that in 2024, Pakistan ...
- Source: drugdu
- 51
- April 27, 2026
Smegglutide begins to fight back

GLP-1 drugs have rapidly become a core segment of the global pharmaceutical market in the past two years. For a long time, the competitive logic of these drugs was highly simplified to a single indicator: the rate of weight loss . Temerpotide, with its higher average weight loss rate demonstrated in clinical trials, has gained a significant cognitive advantage, while its pioneering drug, semaglutide, has gradually been surpassed in this dimension, allowing temerpotide to benefit from its late-mover advantage. This weight-centric assessment method has a natural advantage in terms of dissemination. Weight loss is an intuitive, quantifiable, and quickly comparable indicator, and it is also easier for patients and non-professionals to understand. However, the problem is that this indicator itself cannot distinguish the components of weight loss . Fat loss and lean body mass loss are presented together in weight data, but the two have completely different values in a ...
- Source: drugdu
- 51
- April 27, 2026
Johnson & Johnson’s “Twin Stars” of Immunization Rise

Johnson & Johnson recently released its financial results for the first quarter of 2026. In terms of overall performance, the company achieved sales of US$24.06 billion during the reporting period, representing a year-on-year increase of 9.9%. Johnson & Johnson also raised its full-year guidance: it expects full-year sales in 2026 to reach US$100.3 billion to US$101.3 billion , with a median growth rate of 7.0%. Of these, global revenue from innovative pharmaceuticals grew by 11% to $15.4 billion. Oncology remained the mainstay of performance, with revenue of $6.97 billion, a significant year-on-year increase of 22.8%. However, the immunology business is entering a period of adjustment , with revenue of $3.38 billion, a year-on-year decrease of 8.8%. Stelara, the immunology powerhouse with annual sales of tens of billions of dollars, is shrinking rapidly due to the impact of biosimilars, while Tremfya and Icotyde are emerging as new hope. 01 The Rise ...
- Source: drugdu
- 51
- April 27, 2026
【EXPERT Q&A】What is the function of a ventilator?

Drugdu.com expert’s response: Ventilators: Core Functions, Clinical Applications, and Technological Advances I. Core Functions: From Physiological Replacement to Organ Protection Ventilators achieve three primary functions through mechanical ventilation: Gas Exchange Replacement When patients cannot maintain adequate oxygenation (PaO₂ < 60 mmHg) or CO₂ elimination (PaCO₂ > 50 mmHg) due to pulmonary diseases (e.g., pneumonia, ARDS) or neuromuscular dysfunction (e.g., spinal cord injury), ventilators directly facilitate gas exchange between alveoli and capillaries by setting tidal volume, respiratory rate, and fraction of inspired oxygen (FiO₂). Example: In ARDS patients, alveolar surfactant deficiency causes widespread atelectasis. Ventilators maintain alveolar patency using positive end-expiratory pressure (PEEP), reducing intrapulmonary shunting and improving oxygenation. Respiratory Muscle Unloading During acute exacerbations of chronic obstructive pulmonary disease (COPD), airway obstruction and intrinsic PEEP increase respiratory workload by 3–5 times normal. Ventilators assume partial or full respiratory effort via positive-pressure ventilation, alleviating muscle fatigue and preventing respiratory failure progression. ...
- Source: drugdu
- 79
- April 27, 2026
Guang Sheng Tang-Neraprazole initiated a Phase I clinical trial in China for liver injury and chronic hepatitis B.

On April 23, 2026, Guang Sheng Tang initiated a Phase I clinical trial in China for nerecvir (an HBcAg inhibitor) for the indication of liver injury and chronic hepatitis B. The trial (CTR20261605), titled “Pharmacokinetics and Safety Study of GST-HG141 Tablets in Participants with Impaired and Normal Liver Function,” plans to enroll 24 subjects. The investigational drug in this clinical trial is Neratrovir. The primary endpoints include the following pharmacokinetic parameters: Cmax (maximum plasma concentration), Tmax (time to peak concentration), t1 /2 (half-life), AUC0 -t (area under the curve from dosing to the last detection time), AUC0 -∞ (area under the curve from dosing to infinity), CL/F (apparent clearance), Vz/F (apparent volume of distribution), and plasma protein binding rate. https://bydrug.pharmcube.com/news/detail/794753dd6168e510cf7df98863df6eea
- Source: drugdu
- 80
- April 24, 2026
the global setbacks of FIC

Once a global FIC drug, it has suffered a major setback in the domestic market. According to the NMPA website, Daiichi Sankyo’s Pexidartinib received a “drug notification.” While the specific reason has not been disclosed, this means the drug has not been approved. Of course, this result is not entirely unexpected. After all, while pexidartinib does offer improved patient benefits, its risks cannot be ignored; it had previously been rejected by the EMA in Europe. Meanwhile, in China, pimitinib, with its superior efficacy and safety profile, has already been approved for marketing. To some extent, the failure of Pexidartinib is not just a failure of a single drug, but also reflects a change in the times. With the continuous rise of domestically developed innovative drugs, offering patients better options, domestic regulatory authorities are imposing increasingly higher requirements on drug review and approval. This is especially true for drugs treating non-fatal ...
- Source: drugdu
- 77
- April 24, 2026
Yingpai Pharmaceutical is about to go public.

On April 20, Yingpai Pharmaceutical’s IPO application on the Hong Kong Stock Exchange passed the hearing, meaning it is about to be listed. Founded in 2009, Imbisoft is dedicated to advancing precision oncology therapies based on synthetic lethal mechanisms globally. Imbisoft has built a robust pipeline in the field of synthetic lethality, and is one of only three companies worldwide to simultaneously possess commercially viable PARP1/2 inhibitors and next-generation PARP1 inhibitors in clinical trials. The pipeline for future research and development includes ATR inhibitors, WEE1 inhibitors, SHX9 inhibitors, brain-penetrating PARP1 inhibitors, ATM inhibitors, USP1 inhibitors, CHK1/2 inhibitors, and more. Yingpai Pharmaceutical’s R&D expenditures in 2024 and 2025 were RMB 195 million and RMB 184 million, respectively. As of the end of 2025, Yingpai Pharmaceutical had RMB 259 million in cash on hand. In conclusion , regarding business development (BD) collaborations, Innovent Biologics licensed the overseas rights to its PARP1 inhibitors ...
- Source: drugdu
- 77
- April 24, 2026
Breaking News! The world’s leading medical device company completes a major acquisition.

Recently, Medtronic, the world’s leading medical device company, announced the completion of its acquisition of CathWorks, significantly increasing its investment in the cardiovascular field. Image source: Medtronic official website 01 Cardiovascular track Continue to increase investment CathWorks, founded in 2013, has focused on developing cardiovascular imaging and treatment solutions based on computer vision and artificial intelligence technologies , aiming to provide objective data for percutaneous coronary intervention (PCI) decisions. It’s worth noting that Medtronic’s acquisition of CathWorks was not accidental, but rather the result of nearly eight years of gradual integration. As early as 2018, Medtronic already held a minority stake in CathWorks; in 2022, the relationship between the two parties was further upgraded to a strategic partnership, at which time Medtronic invested approximately US$75 million to jointly promote CathWorks’ core product, the FFRangio system, in the US, European, and Japanese markets . On February 3, 2026, Medtronic officially announced ...
- Source: drugdu
- 77
- April 24, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.